Er-Kim Extends Exclusive Distribution Agreement with Ascendis Pharma A/S to Expand Commercialization of Its Endocrinology Portfolio to Eurasian Markets Er-Kim broadens drug distribution for novel rare endocrinology disease therapies in CEE and Eurasian markets

Er-Kim CEO Cem Zorlular Recognized as a Patient Champion on the 2024 PharmaVoice 100 Cem Zorlular, CEO of Er-Kim recognized as a patient champion in this year's PharmaVoice100